The trial protocol calls for ~80 patients in a 24-week study with topline results projected for early 2021.
The primary endpoint will be a durable hemoglobin response by week 24, defined as Hgb > 10 g/dL and > 2 g/dL greater than baseline.
Currently, fostamatinib is commercially available in U.S. under the brand name TAVALISSE.
Rigel also announced the resignation of Anne-Marie Duliege, Executive VP and CMO, effective August 31. A search for successor is underway.
Subscribe for full text news in your inbox